[Study on the relationship between HIV drug resistance and CD4(+)T cell counts among antiretroviral therapy patients with low viral load]. 2018

P T Liu, and H Xing, and L J Liao, and X B Leng, and J Wang, and W Kan, and J Yan, and Z B Zuo, and Y H Ruan, and Y M Shao
National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

Objective: To explore drug resistance of different viral loads, and investigate the relationship between drug resistance and CD4(+)T cell counts in patients with HIV antiretroviral therapy (ART) in China from 2003 to 2015. Methods: Data were extracted from the Chinese National HIVDR Surveillance database from 2003 to 2015. For this study, the data collected were as follows: having received ART for ≥12 months; 18 years or older; demographic characteristics, information of ART, CD4(+)T cell counts, viral load (VL) and HIV drug resistance of a total of 8 362 patients were collected. Multi-variables non-conditional logistic regression model was used to study the relationship between viral load, HIV drug resistance and CD4(+)T cell counts. Results: Participants with age of (41.8±10.5) years were enrolled in this study. Among them, 59.9% (5 009 cases) were men. The percentage of CD4(+)T cell counts <200 cells/μl in the total population was 17.9% (1 496 cases), the highest was in VL ≥1 000 copies/ml with drug resistance, which was 43.0% (397/923) , followed by VL 50-999 copies/ml with drug resistance, which was 31.1% (69/222), and the lowest was in VL 50-999 copies/ml without drug resistance 13.2% (273/2 068). Compared to VL 50-999 copies/ml without drug resistance, VL<50 copies/ml, VL 50-999 with drug resistance, VL≥1 000 copies/ml without drug resistance, and VL ≥1 000 copies/ml with drug resistance, the OR (95%CI) of CD4 <200 cells/μl were 0.9 (0.7-1.0), 3.2 (2.3-4.4), 2.6 (2.1-3.2), and 4.9 (4.0-5.9), respectively. Among 222 patients with VL 50-999 and HIVDR, the most frequent antiretroviral drugs were EFV and NVP, both of which were NNRTI, and whose percentage both were 94.1% (209 cases). The most frequent mutations were M184V/I (NNRTI), and the percentage was 26.1% (58 cases). The second one was K103N (NNRTI), and the percentage was 22.5% (50 cases). The percentage of V32L/E (PI) and V82A (PI) were lower, they were 0.9% (2 cases) and 0.5% (1 case) respectively. Conclusion: Decreased CD4(+)T cell counts were associated with HIV drug resistance at low viraemia. In the case of low viral load, the most vulnerable were the NNRTI antiviral drugs such as EFV and NVP.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D019562 Viral Load The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression. Viral Burden,Virus Titer,Burden, Viral,Load, Viral,Titer, Virus

Related Publications

P T Liu, and H Xing, and L J Liao, and X B Leng, and J Wang, and W Kan, and J Yan, and Z B Zuo, and Y H Ruan, and Y M Shao
September 2001, Journal of acquired immune deficiency syndromes (1999),
P T Liu, and H Xing, and L J Liao, and X B Leng, and J Wang, and W Kan, and J Yan, and Z B Zuo, and Y H Ruan, and Y M Shao
May 2005, Journal of medical virology,
P T Liu, and H Xing, and L J Liao, and X B Leng, and J Wang, and W Kan, and J Yan, and Z B Zuo, and Y H Ruan, and Y M Shao
January 1999, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
P T Liu, and H Xing, and L J Liao, and X B Leng, and J Wang, and W Kan, and J Yan, and Z B Zuo, and Y H Ruan, and Y M Shao
July 2003, AIDS (London, England),
P T Liu, and H Xing, and L J Liao, and X B Leng, and J Wang, and W Kan, and J Yan, and Z B Zuo, and Y H Ruan, and Y M Shao
September 2002, AIDS research and human retroviruses,
P T Liu, and H Xing, and L J Liao, and X B Leng, and J Wang, and W Kan, and J Yan, and Z B Zuo, and Y H Ruan, and Y M Shao
January 2020, Infectious disorders drug targets,
P T Liu, and H Xing, and L J Liao, and X B Leng, and J Wang, and W Kan, and J Yan, and Z B Zuo, and Y H Ruan, and Y M Shao
April 2013, Journal of the International AIDS Society,
P T Liu, and H Xing, and L J Liao, and X B Leng, and J Wang, and W Kan, and J Yan, and Z B Zuo, and Y H Ruan, and Y M Shao
January 1995, AIDS clinical review,
P T Liu, and H Xing, and L J Liao, and X B Leng, and J Wang, and W Kan, and J Yan, and Z B Zuo, and Y H Ruan, and Y M Shao
June 1996, Annals of internal medicine,
P T Liu, and H Xing, and L J Liao, and X B Leng, and J Wang, and W Kan, and J Yan, and Z B Zuo, and Y H Ruan, and Y M Shao
November 2001, JAMA,
Copied contents to your clipboard!